LANCL3 Inhibitors
LANCL3 inhibitors encompass a range of compounds that interfere with various intracellular signaling cascades, ultimately leading to the reduction of LANCL3 activity. For instance, kinase inhibitors disrupt the kinase-dependent signaling pathways that are essential for the proper cellular context in which LANCL3 functions. When broad-spectrum kinase activity is dampened, the downstream signaling that may regulate LANCL3's activity is also affected. In a similar vein, inhibitors targeting specific signaling molecules such as phosphoinositide 3-kinases or mitogen-activated protein kinase kinase, can lead to an indirect reduction in LANCL3 activity by altering the cell's survival, proliferation, and response pathways. The inhibition of these pathways can change the cellular milieu, which is critical for LANCL3's functionality, thereby indirectly leading to its inhibition.
Other indirect inhibitors exert their effects by modulating cellular processes and environments that are necessary for LANCL3 activity. For example, compounds that inhibit glycolysis or disrupt the Golgi apparatus structure may cause an energy deficit or impair protein trafficking, respectively, both of which could hinder LANCL3 function. Additionally, bioactive lipids that serve as signaling precursors can influence the metabolic pathways that LANCL3 is associated with, altering the protein's activity context. The cellular energy state, a determinant for the functionality of many proteins, can be manipulated by compounds mimicking glucose but impairing its metabolism, thereby potentially reducing LANCL3 activity by creating an unfavorable energetic environment. In the realm of immunological signaling, inhibitors that affect T-cell activation can modify the inflammatory signaling milieu, which might indirectly decrease LANCL3 activity due to a reliance on specific immune pathways for its function. Furthermore, compounds that antagonize calcium signaling or inhibit mTOR pathways can impact the broader cellular signaling environment that supports LANCL3's role, leading to a decrease in its functional activity through indirect modulation of its signaling context.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that by targeting multiple kinases can disrupt downstream signaling pathways. LANCL3's activity is contingent upon the proper signaling context, which would be compromised by the broad kinase inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor that impedes the PI3K/Akt pathway. Since the PI3K/Akt pathway plays a role in cell survival and proliferation, its inhibition could affect the cellular environment necessary for LANCL3 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of mitogen-activated protein kinase kinase (MEK), which blocks the MAPK/ERK pathway. As this pathway influences numerous cellular functions, its inhibition could indirectly affect LANCL3 activity by altering cellular responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAP kinase inhibitor that can alter the inflammatory response pathway. LANCL3, being part of cellular signaling, may have its functional context modified by the inhibition of p38 MAPK-related inflammatory signals. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
A glycolysis inhibitor that mimics glucose but cannot be fully metabolized, leading to energy depletion in cells. The altered energy state can affect the activity of proteins like LANCL3 that are dependent on cellular energy levels. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Binds to cyclophilins and inhibits calcineurin, thereby affecting T-cell activation pathways. As LANCL3 is involved in cellular signaling, its function could be indirectly inhibited by altered T-cell responses. | ||||||
D-erythro-Sphingosine | 123-78-4 | sc-3546 sc-3546A sc-3546B sc-3546C sc-3546D sc-3546E | 10 mg 25 mg 100 mg 1 g 5 g 10 g | $88.00 $190.00 $500.00 $2400.00 $9200.00 $15000.00 | 2 | |
A lipid that serves as a precursor to sphingolipids and as a signaling molecule. By influencing sphingolipid metabolism and signaling pathways, its presence could modify the cellular context in which LANCL3 operates. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factor (Arf), which disrupts Golgi apparatus structure and function. As LANCL3 is a membrane-associated protein, disrupting Golgi function could indirectly impair LANCL3 trafficking and function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that affects cellular growth and metabolism. By altering mTOR signaling, it could indirectly affect LANCL3 activity by changing the cellular environment and signaling context in which LANCL3 functions. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
A potent inhibitor of protein kinase C (PKC), which is involved in various signaling cascades. Inhibition of PKC can alter downstream signaling that might be crucial for the functional regulation of LANCL3. | ||||||